AstraZeneca’s new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small ...

The US Food and Drug Administration has approved AstraZeneca's new tablet formulation of acalabrutinib (Calquence) for all current indications of the capsule version. Approval of the tablet ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...

The tablet version of Calquence, which was approved by the FDA for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia and relapsed/refractory mantle cell lymphoma, may be taken ...

Note: Both CLL and SLL refer to the same disease. The name depends on where the cancer cells are concentrated. With CLL, most cancer cells are found in your blood and bone marrow. With SLL, most ...

Calquence and Brukinsa showed better efficacy and safety than Imbruvica in treating CLL/SLL, with longer TTD and TTNT. Cardiovascular side effects were less frequent with Calquence and Brukinsa ...